Akebia Therapeutics (AKBA) Capital Leases (2013 - 2014)

Akebia Therapeutics (AKBA) reported Capital Leases of $6369.0 for Q2 2014, down 13.51% quarter-over-quarter from $7364.0 in Q1 2014.

Akebia Therapeutics (AKBA) Capital Leases (2013 - 2014) Analysis & Trends

Akebia Therapeutics (AKBA) has 2 years of Capital Leases data on file, last reported at $6369.0 in Q2 2014.

Capital Leases for Q2 2014 came in at $6369.0, changed N/A year-over-year; the trailing twelve-month figure through Jun 2014 was $6369.0 (changed N/A YoY), and the FY2013 annual result was $8004.0, changed N/A from the prior year.
Capital Leases slipped to $6369.0 in Q2 2014 per AKBA's latest filing, from $7364.0 in the prior quarter.
Over five years, Capital Leases peaked at $8004.0 in Q4 2013 and troughed at $6369.0 in Q2 2014.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Teva Pharmaceutical Industries	39.72 Bn	35.98 Bn	1.97 Bn
2	Zoetis	34.61 Bn	32.67 Bn	1.62 Bn
3	United Therapeutics	24.07 Bn	21.91 Bn	648.10 Mn
4	Aurora Cannabis	16.98 Bn	16.91 Bn	33.43 Mn
5	Neurocrine Biosciences	16.64 Bn	15.32 Bn	800.70 Mn
6	Elanco Animal Health	12.19 Bn	11.76 Bn	785.00 Mn
7	Alkermes	7.37 Bn	6.86 Bn	-116.06 Mn
8	Hims & Hers Health	6.62 Bn	5.87 Bn	396.79 Mn
9	Lantheus Holdings	6.47 Bn	5.97 Bn	230.92 Mn
10	Akebia Therapeutics	243.23 Mn	80.63 Mn	41.25 Mn

Download Data